References
Daw S, Hasenclever D, Mascarin M, Fernández-Teijeiro A, Balwierz W,
Beishuizen A, Burnelli R, Cepelova M, Claviez A, Dieckmann K,
Landman-Parker J, Kluge R, Körholz D, Mauz-Körholz C, Wallace WH,
Leblanc T. Risk and Response Adapted Treatment Guidelines for Managing
First Relapsed and Refractory Classical Hodgkin Lymphoma in Children
and Young People. Recommendations from the EuroNet Pediatric Hodgkin
Lymphoma Group. Hemasphere. 2020 Jan 10;4(1):e329.
- Freed J, Kelly KM. Current approaches to the management of pediatric
Hodgkin lymphoma. Paediatr Drugs. 2010 Apr 1;12(2):85-98.
- Kersten MJ, Driessen J, Zijlstra JM, Plattel WJ, Morschhauser F,
Lugtenburg PJ, Brice P, Hutchings M, Gastinne T, Liu R, Burggraaff CN,
Nijland M, Tonino SH, Arens AIJ, Valkema R, van Tinteren H,
Lopez-Yurda M, Diepstra A, De Jong D, Hagenbeek A. Combining
brentuximab vedotin with dexamethasone, high-dose cytarabine and
cisplatin as salvage treatment in relapsed or refractory Hodgkin
lymphoma: the phase II HOVON/LLPC Transplant BRaVE study.
Haematologica. 2021 Apr 1;106(4):1129-1137.
- Forlenza CJ, Gulati N, Mauguen A, Absalon MJ, Castellino SM, Franklin
A, Keller FG, Shukla N. Combination brentuximab vedotin and
bendamustine for pediatric patients with relapsed/refractory Hodgkin
lymphoma. Blood Adv. 2021 Dec 28;5(24):5519-5524.
- Moskowitz CH, Matasar MJ, Zelenetz AD, Nimer SD, Gerecitano J, Hamlin
P, Horwitz S, Moskowitz AJ, Noy A, Palomba L, Perales MA, Portlock C,
Straus D, Maragulia JC, Schoder H, Yahalom J. Normalization of
pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant,
chemotherapy programs improves event-free survival in patients with
Hodgkin lymphoma. Blood. 2012 Feb 16;119(7):1665-70.
- Devillier R, Coso D, Castagna L, Brenot Rossi I, Anastasia A, Chiti A,
Ivanov V, Schiano JM, Santoro A, Chabannon C, Balzarotti M, Blaise D,
Bouabdallah R. Positron emission tomography response at the time of
autologous stem cell transplantation predicts outcome of patients with
relapsed and/or refractory Hodgkin’s lymphoma responding to prior
salvage therapy. Haematologica. 2012 Jul;97(7):1073-9.
- Thomson KJ, Kayani I, Ardeshna K, Morris EC, Hough R, Virchis A,
Goldstone AH, Linch DC, Peggs KS. A response-adjusted PET-based
transplantation strategy in primary resistant and relapsed Hodgkin
Lymphoma. Leukemia. 2013 Jun;27(6):1419-22.
- Gorde-Grosjean S, Oberlin O, Leblanc T, Pacquement H, Donadieu J,
Lambilliotte A, Schell M, Dommange F, Munzer M, Paillard C, Schmitt C,
Lutz P, Edan C, Ansoborlo S, Stephan JL, Michel G, Thomas C, Perel Y,
Robert A, Landman-Parker J. Outcome of children and adolescents with
recurrent/refractory classical Hodgkin lymphoma, a study from the
Société Française de Lutte contre le Cancer des Enfants et des
Adolescents (SFCE). Br J Haematol. 2012 Sep;158(5):649-56.
- Shafer JA, Heslop HE, Brenner MK, Carrum G, Wu MF, Liu H, Ahmed N,
Gottschalk S, Kamble R, Leung KS, Myers GD, Bollard CM, Krance RA.
Outcome of hematopoietic stem cell transplant as salvage therapy for
Hodgkin’s lymphoma in adolescents and young adults at a single
institution. Leuk Lymphoma. 2010 Apr;51(4):664-70.
- Ansell SM. Hodgkin lymphoma: A 2020 update on diagnosis,
risk-stratification, and management. Am J Hematol. 2020
Aug;95(8):978-989.
- Voorhees TJ, Beaven AW. Therapeutic Updates for Relapsed and
Refractory Classical Hodgkin Lymphoma. Cancers (Basel). 2020 Oct
8;12(10):2887.
- Josting A, Rudolph C, Reiser M, Mapara M, Sieber M, Kirchner HH,
Dörken B, Hossfeld DK, Diehl V, Engert A; Participating Centers.
Time-intensified dexamethasone/cisplatin/cytarabine: an effective
salvage therapy with low toxicity in patients with relapsed and
refractory Hodgkin’s disease. Ann Oncol. 2002 Oct;13(10):1628-35.
- Velasquez WS, Cabanillas F, Salvador P, McLaughlin P, Fridrik M,
Tucker S, Jagannath S, Hagemeister FB, Redman JR, Swan F, et al.
Effective salvage therapy for lymphoma with cisplatin in combination
with high-dose Ara-C and dexamethasone (DHAP). Blood. 1988
Jan;71(1):117-22.
- Plattel WJ, Bergamasco A, Trinchese F, Gavini F, Bent-Ennakhil N,
Zomas A, Castillon G, Arredondo-Bisono T, Cristarella T, Moride Y, von
Tresckow B. Effectiveness of brentuximab vedotin monotherapy in
relapsed or refractory Hodgkin lymphoma: a systematic review and
meta-analysis. Leuk Lymphoma. 2021 Dec;62(14):3320-3332.
- Locatelli F, Mauz-Koerholz C, Neville K, Llort A, Beishuizen A, Daw S,
Pillon M, Aladjidi N, Klingebiel T, Landman-Parker J, Medina-Sanson A,
August K, Sachs J, Hoffman K, Kinley J, Song S, Song G, Zhang S, Suri
A, Gore L. Brentuximab vedotin for paediatric relapsed or refractory
Hodgkin’s lymphoma and anaplastic large-cell lymphoma: a multicentre,
open-label, phase 1/2 study. Lancet Haematol. 2018
Oct;5(10):e450-e461.
- Massano D, Carraro E, Mussolin L, Buffardi S, Barat V, Zama D, Muggeo
P, Vendemini F, Sau A, Moleti ML, Verzegnassi F, D’Amico S, Casini T,
Garaventa A, Schiavello E, Cellini M, Vinti L, Farruggia P, Perruccio
K, Cesaro S, De Santis R, Marinoni M, D’Alba I, Mura RM, Burnelli R,
Mascarin M, Pillon M. Brentuximab vedotin in the treatment of
paediatric patients with relapsed or refractory Hodgkin’s lymphoma:
Results of a real-life study. Pediatr Blood Cancer. 2022
Oct;69(10):e29801.
- Vinti L, Pagliara D, Buffardi S, Di Ruscio V, Stocchi F, Mariggiò E,
Parasole R, Di Matteo A, Petruzziello F, Paganelli V, De Vito R, Del
Bufalo F, Strocchio L, Locatelli F. Brentuximab vedotin in combination
with bendamustine in pediatric patients or young adults with relapsed
or refractory Hodgkin lymphoma. Pediatr Blood Cancer. 2022
Apr;69(4):e29557.
- Moskowitz CH, Walewski J, Nademanee A, Masszi T, Agura E, Holowiecki
J, Abidi MH, Chen AI, Stiff P, Viviani S, Bachanova V, Sureda A,
McClendon T, Lee C, Lisano J, Sweetenham J. Five-year PFS from the
AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk
of progression or relapse. Blood. 2018 Dec 20;132(25):2639-2642. doi:
10.1182/blood-2018-07-861641. Epub 2018 Sep 28.
LegendsFigure 1 Schematic overview of the BV-DHAP regimen. Drugs with
their dosage are indicated on the left. Cycles were delivered every 21
days
Table 1 Clinical characteristics of the two patients